日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The histone modifier KAT2A presents a selective target in a subset of well-differentiated microsatellite-stable colorectal cancers.

组蛋白修饰因子 KAT2A 在一部分分化良好的微卫星稳定型结直肠癌中是一个选择性靶点

Kufrin Vida, Seiler Annika, Brilloff Silke, Rothfuß Helen, Küchler Sandra, Schäfer Silvia, Rahimian Elahe, Baumgarten Jonas, Ding Li, Buchholz Frank, Ball Claudia R, Bornhäuser Martin, Glimm Hanno, Bill Marius, Wurm Alexander A

Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia

细胞周期调节因子MYBL2是急性髓系白血病的一个独特弱点。

Sandra Küchler ,Silke Brilloff ,Silvia Schäfer ,Elahe Rahimian ,Vida Kufrin ,Shraddha S Peri ,Julian Musa ,Thomas G P Grünewald ,Denis M Schewe ,Claudia R Ball ,Martin Bornhäuser ,Hanno Glimm ,Marius Bill # ,Alexander A Wurm #

Regulation of multiple signaling pathways promotes the consistent expansion of human pancreatic progenitors in defined conditions

在特定条件下,多种信号通路的调控促进了人类胰腺祖细胞的持续扩增。

Luka Jarc # ,Manuj Bandral # ,Elisa Zanfrini ,Mathias Lesche ,Vida Kufrin ,Raquel Sendra ,Daniela Pezzolla ,Ioannis Giannios ,Shahryar Khattak ,Katrin Neumann ,Barbara Ludwig ,Anthony Gavalas

Generation and application of novel hES cell reporter lines for the differentiation and maturation of hPS cell-derived islet-like clusters

新型 hES 细胞报告系的生成和应用,用于 hPS 细胞衍生的胰岛样簇的分化和成熟

Elisa Zanfrini #, Manuj Bandral #, Luka Jarc, Maria Alejandra Ramirez-Torres, Daniela Pezzolla, Vida Kufrin, Eva Rodriguez-Aznar, Ana Karen Mojica Avila, Christian Cohrs, Stephan Speier, Katrin Neumann, Anthony Gavalas

Signaling-induced systematic repression of miRNAs uncovers cancer vulnerabilities and targeted therapy sensitivity

信号诱导的 miRNA 系统性抑制揭示了癌症的脆弱性和靶向治疗敏感性

Alexander A Wurm, Silke Brilloff, Sofia Kolovich, Silvia Schäfer, Elahe Rahimian, Vida Kufrin, Marius Bill, Zunamys I Carrero, Stephan Drukewitz, Alexander Krüger, Melanie Hüther, Sebastian Uhrig, Sandra Oster, Dana Westphal, Friedegund Meier, Katrin Pfütze, Daniel Hübschmann, Peter Horak, Simon Kre

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

FDA批准摘要:Futibatinib用于治疗不可切除的晚期或转移性、化疗难治性肝内胆管癌,伴有FGFR2融合或其他重排

Gandhy, Shruti U; Casak, Sandra J; Mushti, Sirisha L; Cheng, Joyce; Subramaniam, Sriram; Zhao, Hong; Zhao, Miao; Bi, Youwei; Liu, Guansheng; Fan, Jianghong; Adeniyi, Oluseyi; Charlab, Rosane; Kufrin, Dubravka; Thompson, Matthew D; Jarrell, Kristin; Auth, Doris; Lemery, Steven J; Pazdur, Richard; Kluetz, Paul G; Fashoyin-Aje, Lola A